Inside Sana Biotechnology's plans to go public
Well, we've made it to the final day of this year's virtual J.P. Morgan
One of biotech's most valuable startups just filed to go public. Here are 5 crucial takeaways from Sana's 271-page filing.
Sana Biotechnologyhas filed to go public.
- The secretive Seattle-based biotech has raised $705.5 million since it was founded in July 2018.
- We dug through its 271-page filing to unearth five key details on Sana's financials, strategy, and future.
$1.5 billion digital-health startup Ro wants to be your online doctor. Here's how its coronavirus response rooted in rapid at-home testing fits into the new unicorn's long-term strategy.
- Ro, the direct-to-consumer digital health startup, announced Wednesday that it will teaming up with computer-vision startup Gauss to offer at-home rapid COVID-19 antigen tests.
- The partnership will start once Gauss's test gets an emergency use authorization from the FDA.
- The news comes roughly a month after Ro announced it was acquiring at-home blood-testing startup Workpath, further indicating the startup's ambitions to grow well beyond its roots in mail-order prescriptions for hair loss or erectile dysfunction.
A top biotech investor lays out why an entirely new approach to treating cancer and infections could finally pay off in 2021
- A top healthcare VC predicted
microbiomedrugs would rebound in 2021 as part of Business Insider's year-end roundup of healthcare predictions.
- Though the biotech industry's infatuation with the promise of the bacteria in our gut dates back years, research failures and the 2019 uBiome scandal previously chilled investors' interests.
- More established microbiome companies have continued the search to prove the microbiome can bear fruit for patients and investors alike.
- Silicon Valley billionaire investor Vinod Khosla said involving industry insiders in Pfizer and BioNTech's vaccine early in development 'would have slowed down' progress (Business Insider)
- Is it ethical to get vaccinated before your turn? One bioethicist argues yes (Elemental)
- Fertility benefits company Progyny lost 85% of its business at the start of the pandemic. Here's how its CEO is ramping up an aggressive growth strategy fueled by acquisitions. (Business Insider)
- Talkspace is going public via SPAC in a deal that values the company at $1.4 billion (Stat News)
- Walgreens is teasing a 200-person in-house startup that aims to improve healthcare. Here's what to know. (Business Insider)
- SCOOP: Trump's promise to send people $200 drug discount cards isn't happening, Medicare chief says (Business Insider)
- Reddit recovers from a major outage as GameStop shares soar over 100%
- Nureca stocks debut on bourses at 59% premium over IPO price
- How Airtel’s AdTech platform is planning to deliver on the promise of ‘zero ad frauds’ to its clients
- Traffic jam on the Ganga - one of India's largest rivers will now get lane separators to deal with crowded boats
- Synology DiskStation DS220+ review – the perfect cloud replacement for backing up photos and files